Anthrax immune globulin human

Identification

Name
Anthrax immune globulin human
Accession Number
DB09057
Type
Biotech
Groups
Approved
Biologic Classification
Protein Based Therapies
Polyclonal antibody (pAb)
Description

Anthrax immune globulin is a human immune globulin that is used in combination with antibiotics to treat anthrax. It is derived from the plasma of humans immunized with BioThrax (adsorbed anthrax vaccine), which is then further purified. Available as the product Anthrasil (FDA), the result is a solution for slow IV infusion containing polyclonal antibodies that bind the protective antigen (PA) component of Bacillus anthracis lethal and edema toxins. This binding of antibody to PA prevents PA-mediated cellular entry of toxic factors. It is administered in combination with appropriate antibiotic therapy as the immunoglobulin itself is not known to have direct antibacterial activity against anthrax bacteria, which otherwise may continue to grow and produce anthrax toxins.

Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
  • Anthrax immune globulin (human)
  • Anthrax immune globulin human
  • Bacillus anthracis immune globulin human
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AnthrasilLiquid60 [iU]/35mLIntravenousCangene Corporation2015-10-05Not applicableUs
AnthrasilSolution60 unitIntravenousEmergent Biosolutions Canada IncNot applicableNot applicableCanada
Categories
UNII
VKZ83S945Z
CAS number
Not Available

Pharmacology

Indication

Anthrax immune globulin is indicated for the treatment of inhalational anthrax in adult and pediatric patients in combination with appropriate antibacterial drugs.

Structured Indications
Pharmacodynamics
Not Available
Mechanism of action

Polyclonal anthrax immune globulin is a passive immunizing agent that neutralizes anthrax toxin by binding to Protective Antigen (PA) to prevent PA-mediated cellular entry of anthrax edema factor and lethal factor. It is administered in combination with appropriate antibiotic therapy as the immunoglobulin itself is not known to have direct antibacterial activity against anthrax bacteria, which otherwise may continue to grow and produce anthrax toxins.

TargetActionsOrganism
AProtective antigen
antibody
Bacillus anthracis
Absorption

Peak levels were reached immediately after infusion and then declined over the duration of study (84 days). Mean activity remained above the lower limit of quantitation (5 milliunits per mL) over the entire 84-day post-dose period for the three doses studied. Cmax was found to be 83.0 mU/mL while Tmax was found to be 0.116 days.

Volume of distribution

5714.8 mL

Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life

24.3 days

Clearance

174.2 mL/day

Toxicity

The most common adverse reactions to Anthrasil observed in >5% of healthy volunteers in clinical trials were headache, infusion site pain and swelling, nausea, and back pain.

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Anthrax immune globulin human.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Anthrax immune globulin human.Experimental, Illicit
2-MethoxyethanolThe risk or severity of adverse effects can be increased when 2-Methoxyethanol is combined with Anthrax immune globulin human.Experimental
5-androstenedioneThe risk or severity of adverse effects can be increased when 5-androstenedione is combined with Anthrax immune globulin human.Experimental, Illicit
AbataceptThe risk or severity of adverse effects can be increased when Abatacept is combined with Anthrax immune globulin human.Approved
AbciximabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Abciximab.Approved
AbetimusThe risk or severity of adverse effects can be increased when Abetimus is combined with Anthrax immune globulin human.Investigational
AbituzumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Abituzumab.Investigational
ActeosideThe risk or severity of adverse effects can be increased when Acteoside is combined with Anthrax immune globulin human.Investigational
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Anthrax immune globulin human.Approved
AdecatumumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Adecatumumab.Investigational
AdefovirThe risk or severity of adverse effects can be increased when Adefovir is combined with Anthrax immune globulin human.Investigational
AducanumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Aducanumab.Investigational
AfelimomabThe risk or severity of adverse effects can be increased when Afelimomab is combined with Anthrax immune globulin human.Investigational
AlclometasoneThe risk or severity of adverse effects can be increased when Alclometasone is combined with Anthrax immune globulin human.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Aldosterone is combined with Anthrax immune globulin human.Experimental, Investigational
AlefaceptThe risk or severity of adverse effects can be increased when Alefacept is combined with Anthrax immune globulin human.Approved, Investigational, Withdrawn
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Anthrax immune globulin human.Approved, Investigational
AlicaforsenThe risk or severity of adverse effects can be increased when Alicaforsen is combined with Anthrax immune globulin human.Investigational
AlirocumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Alirocumab.Approved
AltretamineThe risk or severity of adverse effects can be increased when Altretamine is combined with Anthrax immune globulin human.Approved
AmatuximabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Amatuximab.Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Amcinonide is combined with Anthrax immune globulin human.Approved
AMG 108The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with AMG 108.Investigational
AmsacrineThe risk or severity of adverse effects can be increased when Amsacrine is combined with Anthrax immune globulin human.Approved, Investigational
AnakinraThe risk or severity of adverse effects can be increased when Anakinra is combined with Anthrax immune globulin human.Approved
AndrostenedioneThe risk or severity of adverse effects can be increased when Androstenedione is combined with Anthrax immune globulin human.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Anecortave is combined with Anthrax immune globulin human.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Anthrax immune globulin human.Investigational
AnifrolumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Anifrolumab.Investigational
Antilymphocyte immunoglobulin (horse)The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Anthrax immune globulin human.Approved, Investigational
Antithymocyte immunoglobulin (rabbit)The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Anthrax immune globulin human.Approved
ApolizumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Apolizumab.Investigational
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Anthrax immune globulin human.Approved, Investigational
AscrinvacumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Ascrinvacumab.Investigational
Asfotase AlfaThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Asfotase Alfa.Approved, Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Atamestane is combined with Anthrax immune globulin human.Investigational
AtezolizumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Atezolizumab.Approved, Investigational
AVE9633The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with AVE9633.Investigational
AvelumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Avelumab.Approved, Investigational
AzacitidineThe risk or severity of adverse effects can be increased when Azacitidine is combined with Anthrax immune globulin human.Approved, Investigational
AzathioprineThe risk or severity of adverse effects can be increased when Azathioprine is combined with Anthrax immune globulin human.Approved
BapineuzumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Bapineuzumab.Investigational
BasiliximabThe risk or severity of adverse effects can be increased when Basiliximab is combined with Anthrax immune globulin human.Approved, Investigational
BavituximabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Bavituximab.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Anthrax immune globulin human.Approved, Investigational
BectumomabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Bectumomab.Investigational
BegelomabThe risk or severity of adverse effects can be increased when Begelomab is combined with Anthrax immune globulin human.Experimental, Investigational
BelataceptThe risk or severity of adverse effects can be increased when Belatacept is combined with Anthrax immune globulin human.Approved, Investigational
BelimumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Belimumab.Approved
BenznidazoleThe risk or severity of adverse effects can be increased when Benznidazole is combined with Anthrax immune globulin human.Approved, Investigational
BesilesomabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Besilesomab.Approved
BetamethasoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with Anthrax immune globulin human.Approved, Vet Approved
BevacizumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Bevacizumab.Approved, Investigational
BIIB015The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with BIIB015.Investigational
BimagrumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Bimagrumab.Investigational
BivatuzumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Bivatuzumab.Investigational
BleomycinThe risk or severity of adverse effects can be increased when Bleomycin is combined with Anthrax immune globulin human.Approved, Investigational
BlinatumomabThe risk or severity of adverse effects can be increased when Blinatumomab is combined with Anthrax immune globulin human.Approved, Investigational
BlosozumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Blosozumab.Investigational
BococizumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Bococizumab.Investigational
Brentuximab vedotinThe risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Anthrax immune globulin human.Approved, Investigational
BriakinumabThe risk or severity of adverse effects can be increased when Briakinumab is combined with Anthrax immune globulin human.Investigational
BrodalumabThe risk or severity of adverse effects can be increased when Brodalumab is combined with Anthrax immune globulin human.Approved, Investigational
BudesonideThe risk or severity of adverse effects can be increased when Budesonide is combined with Anthrax immune globulin human.Approved
BusulfanThe risk or severity of adverse effects can be increased when Busulfan is combined with Anthrax immune globulin human.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Anthrax immune globulin human.Approved
CanakinumabThe risk or severity of adverse effects can be increased when Canakinumab is combined with Anthrax immune globulin human.Approved, Investigational
CapecitabineThe risk or severity of adverse effects can be increased when Capecitabine is combined with Anthrax immune globulin human.Approved, Investigational
CaplacizumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Caplacizumab.Investigational
Capromab pendetideThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Capromab pendetide.Approved
CarboplatinThe risk or severity of adverse effects can be increased when Carboplatin is combined with Anthrax immune globulin human.Approved
CarlumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Carlumab.Investigational
CarmustineThe risk or severity of adverse effects can be increased when Carmustine is combined with Anthrax immune globulin human.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Anthrax immune globulin human.Experimental
CatumaxomabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Catumaxomab.Approved, Investigational, Withdrawn
Certolizumab pegolThe risk or severity of adverse effects can be increased when Certolizumab pegol is combined with Anthrax immune globulin human.Approved
CetuximabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Cetuximab.Approved
ChlorambucilThe risk or severity of adverse effects can be increased when Chlorambucil is combined with Anthrax immune globulin human.Approved
ChlorotrianiseneChlorotrianisene may increase the thrombogenic activities of Anthrax immune globulin human.Investigational, Withdrawn
CiclesonideThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Anthrax immune globulin human.Approved, Investigational
CisplatinThe risk or severity of adverse effects can be increased when Cisplatin is combined with Anthrax immune globulin human.Approved
CixutumumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Cixutumumab.Investigational
CladribineThe risk or severity of adverse effects can be increased when Cladribine is combined with Anthrax immune globulin human.Approved, Investigational
ClazakizumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Clazakizumab.Investigational
ClenoliximabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Clenoliximab.Investigational
ClobetasolThe risk or severity of adverse effects can be increased when Clobetasol is combined with Anthrax immune globulin human.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Anthrax immune globulin human.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Clobetasone is combined with Anthrax immune globulin human.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Clocortolone is combined with Anthrax immune globulin human.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Anthrax immune globulin human.Approved, Investigational
Coltuximab ravtansineThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Coltuximab ravtansine.Investigational
ConatumumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Conatumumab.Investigational
ConcizumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Concizumab.Investigational
Conjugated estrogensConjugated estrogens may increase the thrombogenic activities of Anthrax immune globulin human.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Cortexolone 17α-propionate is combined with Anthrax immune globulin human.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Corticosterone is combined with Anthrax immune globulin human.Experimental
CorticotropinThe risk or severity of adverse effects can be increased when Corticotropin is combined with Anthrax immune globulin human.Approved, Investigational, Vet Approved
Cortisone acetateThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Anthrax immune globulin human.Approved, Investigational
CR002The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with CR002.Investigational
CrenezumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Crenezumab.Investigational
CrotedumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Crotedumab.Investigational
CyclophosphamideThe risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Anthrax immune globulin human.Approved, Investigational
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Anthrax immune globulin human.Approved, Investigational, Vet Approved
CytarabineThe risk or severity of adverse effects can be increased when Cytarabine is combined with Anthrax immune globulin human.Approved, Investigational
DacarbazineThe risk or severity of adverse effects can be increased when Dacarbazine is combined with Anthrax immune globulin human.Approved, Investigational
DacetuzumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Dacetuzumab.Investigational
DaclizumabThe risk or severity of adverse effects can be increased when Daclizumab is combined with Anthrax immune globulin human.Investigational, Withdrawn
DactinomycinThe risk or severity of adverse effects can be increased when Dactinomycin is combined with Anthrax immune globulin human.Approved, Investigational
DaidzeinDaidzein may increase the thrombogenic activities of Anthrax immune globulin human.Experimental
DalotuzumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Dalotuzumab.Investigational
DaratumumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Daratumumab.Approved
DasatinibThe risk or severity of adverse effects can be increased when Dasatinib is combined with Anthrax immune globulin human.Approved, Investigational
DaunorubicinThe risk or severity of adverse effects can be increased when Daunorubicin is combined with Anthrax immune globulin human.Approved
DeflazacortThe risk or severity of adverse effects can be increased when Deflazacort is combined with Anthrax immune globulin human.Approved, Investigational
DemcizumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Demcizumab.Investigational
DenosumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Denosumab.Approved
DeoxyspergualinThe risk or severity of adverse effects can be increased when Deoxyspergualin is combined with Anthrax immune globulin human.Investigational
DepatuxizumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Depatuxizumab.Investigational
DesonideThe risk or severity of adverse effects can be increased when Desonide is combined with Anthrax immune globulin human.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Anthrax immune globulin human.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Desoxycorticosterone acetate is combined with Anthrax immune globulin human.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Anthrax immune globulin human.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Anthrax immune globulin human.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Dexamethasone isonicotinate is combined with Anthrax immune globulin human.Vet Approved
DienestrolDienestrol may increase the thrombogenic activities of Anthrax immune globulin human.Approved, Investigational
DiethylstilbestrolDiethylstilbestrol may increase the thrombogenic activities of Anthrax immune globulin human.Approved, Investigational
DiflorasoneThe risk or severity of adverse effects can be increased when Diflorasone is combined with Anthrax immune globulin human.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Anthrax immune globulin human.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Difluprednate is combined with Anthrax immune globulin human.Approved
Dimethyl fumarateThe risk or severity of adverse effects can be increased when Dimethyl fumarate is combined with Anthrax immune globulin human.Approved, Investigational
DinutuximabThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Anthrax immune globulin human.Approved, Investigational
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Anthrax immune globulin human.Approved, Investigational
DoxifluridineThe risk or severity of adverse effects can be increased when Doxifluridine is combined with Anthrax immune globulin human.Investigational
DoxorubicinThe risk or severity of adverse effects can be increased when Doxorubicin is combined with Anthrax immune globulin human.Approved, Investigational
DulaglutideThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Dulaglutide.Approved, Investigational
DuligotuzumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Duligotuzumab.Investigational
DupilumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Dupilumab.Approved, Investigational
DurvalumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Durvalumab.Approved, Investigational
DusigitumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Dusigitumab.Investigational
EculizumabThe risk or severity of adverse effects can be increased when Eculizumab is combined with Anthrax immune globulin human.Approved, Investigational
EdrecolomabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Edrecolomab.Experimental, Investigational
EfalizumabThe risk or severity of adverse effects can be increased when Efalizumab is combined with Anthrax immune globulin human.Approved, Investigational
EldelumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Eldelumab.Investigational
ElotuzumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Elotuzumab.Approved
EmibetuzumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Emibetuzumab.Investigational
EmicizumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Emicizumab.Approved, Investigational
EnokizumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Enokizumab.Investigational
EpimestrolEpimestrol may increase the thrombogenic activities of Anthrax immune globulin human.Experimental
EpirubicinThe risk or severity of adverse effects can be increased when Epirubicin is combined with Anthrax immune globulin human.Approved
EpratuzumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Epratuzumab.Investigational
EquileninThe risk or severity of adverse effects can be increased when Equilenin is combined with Anthrax immune globulin human.Experimental
EquilinThe risk or severity of adverse effects can be increased when Equilin is combined with Anthrax immune globulin human.Approved
EquolEquol may increase the thrombogenic activities of Anthrax immune globulin human.Investigational
EstradiolEstradiol may increase the thrombogenic activities of Anthrax immune globulin human.Approved, Investigational, Vet Approved
Estradiol acetateEstradiol acetate may increase the thrombogenic activities of Anthrax immune globulin human.Approved, Investigational, Vet Approved
Estradiol cypionateEstradiol cypionate may increase the thrombogenic activities of Anthrax immune globulin human.Approved, Investigational, Vet Approved
Estradiol valerateEstradiol valerate may increase the thrombogenic activities of Anthrax immune globulin human.Approved, Investigational, Vet Approved
EstramustineThe risk or severity of adverse effects can be increased when Estramustine is combined with Anthrax immune globulin human.Approved, Investigational
EstriolEstriol may increase the thrombogenic activities of Anthrax immune globulin human.Approved, Investigational, Vet Approved
Estrogens, esterifiedEstrogens, esterified may increase the thrombogenic activities of Anthrax immune globulin human.Approved
EstroneEstrone may increase the thrombogenic activities of Anthrax immune globulin human.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Anthrax immune globulin human.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Anthrax immune globulin human.Approved, Investigational
EtaracizumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Etaracizumab.Investigational
Ethinyl EstradiolEthinyl Estradiol may increase the thrombogenic activities of Anthrax immune globulin human.Approved
EtoposideThe risk or severity of adverse effects can be increased when Etoposide is combined with Anthrax immune globulin human.Approved
EtrolizumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Etrolizumab.Investigational
EverolimusThe risk or severity of adverse effects can be increased when Everolimus is combined with Anthrax immune globulin human.Approved
EvolocumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Evolocumab.Approved
FarletuzumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Farletuzumab.Investigational
FiclatuzumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Ficlatuzumab.Investigational
FigitumumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Figitumumab.Investigational
FingolimodThe risk or severity of adverse effects can be increased when Fingolimod is combined with Anthrax immune globulin human.Approved, Investigational
FirategrastThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Firategrast.Investigational
FloxuridineThe risk or severity of adverse effects can be increased when Floxuridine is combined with Anthrax immune globulin human.Approved
FluasteroneThe risk or severity of adverse effects can be increased when Fluasterone is combined with Anthrax immune globulin human.Investigational
FludarabineThe risk or severity of adverse effects can be increased when Fludarabine is combined with Anthrax immune globulin human.Approved
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Anthrax immune globulin human.Approved, Investigational
FlumethasoneThe risk or severity of adverse effects can be increased when Flumethasone is combined with Anthrax immune globulin human.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Flunisolide is combined with Anthrax immune globulin human.Approved, Investigational
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Anthrax immune globulin human.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Anthrax immune globulin human.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Fluocortolone is combined with Anthrax immune globulin human.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Anthrax immune globulin human.Approved, Investigational
FluorouracilThe risk or severity of adverse effects can be increased when Fluorouracil is combined with Anthrax immune globulin human.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Fluprednidene is combined with Anthrax immune globulin human.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Fluprednisolone is combined with Anthrax immune globulin human.Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Anthrax immune globulin human.Approved
Fluticasone furoateThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Anthrax immune globulin human.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Anthrax immune globulin human.Approved
FontolizumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Fontolizumab.Investigational
FormestaneThe risk or severity of adverse effects can be increased when Formestane is combined with Anthrax immune globulin human.Approved, Investigational, Withdrawn
FresolimumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Fresolimumab.Investigational
FulranumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Fulranumab.Investigational
GaliximabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Galiximab.Investigational
Gallium nitrateThe risk or severity of adverse effects can be increased when Gallium nitrate is combined with Anthrax immune globulin human.Approved, Investigational
GanitumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Ganitumab.Investigational
GantenerumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Gantenerumab.Investigational
GemcitabineThe risk or severity of adverse effects can be increased when Gemcitabine is combined with Anthrax immune globulin human.Approved
Gemtuzumab ozogamicinThe risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Anthrax immune globulin human.Approved, Investigational
GenisteinGenistein may increase the thrombogenic activities of Anthrax immune globulin human.Investigational
GevokizumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Gevokizumab.Investigational
Glatiramer AcetateThe risk or severity of adverse effects can be increased when Glatiramer Acetate is combined with Anthrax immune globulin human.Approved, Investigational
Glembatumumab vedotinThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Glembatumumab vedotin.Investigational
GlimepirideThe risk or severity of adverse effects can be increased when Glimepiride is combined with Anthrax immune globulin human.Approved
GolimumabThe risk or severity of adverse effects can be increased when Golimumab is combined with Anthrax immune globulin human.Approved
GS 0573The risk or severity of adverse effects can be increased when GS 0573 is combined with Anthrax immune globulin human.Investigational
GuselkumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Guselkumab.Approved, Investigational
GusperimusThe risk or severity of adverse effects can be increased when Gusperimus is combined with Anthrax immune globulin human.Investigational
HalcinonideThe risk or severity of adverse effects can be increased when Halcinonide is combined with Anthrax immune globulin human.Approved, Investigational, Withdrawn
HE3286The risk or severity of adverse effects can be increased when HE3286 is combined with Anthrax immune globulin human.Investigational
HexestrolHexestrol may increase the thrombogenic activities of Anthrax immune globulin human.Withdrawn
Human C1-esterase inhibitorThe risk or severity of adverse effects can be increased when Human C1-esterase inhibitor is combined with Anthrax immune globulin human.Approved
Human cytomegalovirus immune globulinThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Human cytomegalovirus immune globulin.Approved
Human Varicella-Zoster Immune GlobulinThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Human Varicella-Zoster Immune Globulin.Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Anthrax immune globulin human.Approved, Vet Approved
HydroxyureaThe risk or severity of adverse effects can be increased when Hydroxyurea is combined with Anthrax immune globulin human.Approved
HypericinThe risk or severity of adverse effects can be increased when Hypericin is combined with Anthrax immune globulin human.Investigational
IbalizumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Ibalizumab.Approved, Investigational
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Anthrax immune globulin human.Approved, Investigational
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Anthrax immune globulin human.Approved
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Anthrax immune globulin human.Approved, Investigational
IdarubicinThe risk or severity of adverse effects can be increased when Idarubicin is combined with Anthrax immune globulin human.Approved
IdarucizumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Idarucizumab.Approved
IdelalisibThe risk or severity of adverse effects can be increased when Idelalisib is combined with Anthrax immune globulin human.Approved
IfosfamideThe risk or severity of adverse effects can be increased when Ifosfamide is combined with Anthrax immune globulin human.Approved
IGN311The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with IGN311.Investigational
ImatinibThe risk or severity of adverse effects can be increased when Imatinib is combined with Anthrax immune globulin human.Approved
IMC-1C11The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with IMC-1C11.Investigational
ImiquimodThe risk or severity of adverse effects can be increased when Imiquimod is combined with Anthrax immune globulin human.Approved, Investigational
Immune Globulin HumanThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Immune Globulin Human.Approved, Investigational
InclacumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Inclacumab.Investigational
Indium In-111 satumomab pendetideThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Indium In-111 satumomab pendetide.Approved, Withdrawn
InebilizumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Inebilizumab.Investigational
InfliximabThe risk or severity of adverse effects can be increased when Infliximab is combined with Anthrax immune globulin human.Approved
Inotuzumab ozogamicinThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Inotuzumab ozogamicin.Approved, Investigational
IntetumumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Intetumumab.Investigational
IPH 2101The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with IPH 2101.Investigational
IpilimumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Ipilimumab.Approved
IratumumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Iratumumab.Investigational
IrinotecanThe risk or severity of adverse effects can be increased when Irinotecan is combined with Anthrax immune globulin human.Approved, Investigational
IstaroximeThe risk or severity of adverse effects can be increased when Istaroxime is combined with Anthrax immune globulin human.Investigational
IxekizumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Ixekizumab.Approved, Investigational
L-PhenylalanineThe risk or severity of adverse effects can be increased when L-Phenylalanine is combined with Anthrax immune globulin human.Approved, Investigational, Nutraceutical
LabetuzumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Labetuzumab.Investigational
LampalizumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Lampalizumab.Investigational
LandogrozumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Landogrozumab.Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Anthrax immune globulin human.Approved, Investigational
LenalidomideThe risk or severity of adverse effects can be increased when Lenalidomide is combined with Anthrax immune globulin human.Approved
LerdelimumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Lerdelimumab.Investigational
LexatumumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Lexatumumab.Investigational
LigelizumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Ligelizumab.Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Anthrax immune globulin human.Investigational
LomustineThe risk or severity of adverse effects can be increased when Lomustine is combined with Anthrax immune globulin human.Approved, Investigational
Lorvotuzumab mertansineThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Lorvotuzumab mertansine.Investigational
LoteprednolThe risk or severity of adverse effects can be increased when Loteprednol is combined with Anthrax immune globulin human.Approved
LucatumumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Lucatumumab.Investigational
LumiliximabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Lumiliximab.Investigational
MatuzumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Matuzumab.Investigational
MavrilimumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Mavrilimumab.Investigational
ME-609The risk or severity of adverse effects can be increased when ME-609 is combined with Anthrax immune globulin human.Investigational
MechlorethamineThe risk or severity of adverse effects can be increased when Mechlorethamine is combined with Anthrax immune globulin human.Approved, Investigational
MedrysoneThe risk or severity of adverse effects can be increased when Medrysone is combined with Anthrax immune globulin human.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Melengestrol is combined with Anthrax immune globulin human.Vet Approved
MelphalanThe risk or severity of adverse effects can be increased when Melphalan is combined with Anthrax immune globulin human.Approved
MepolizumabThe risk or severity of adverse effects can be increased when Mepolizumab is combined with Anthrax immune globulin human.Approved, Investigational
MercaptopurineThe risk or severity of adverse effects can be increased when Mercaptopurine is combined with Anthrax immune globulin human.Approved
MestranolMestranol may increase the thrombogenic activities of Anthrax immune globulin human.Approved
MethallenestrilMethallenestril may increase the thrombogenic activities of Anthrax immune globulin human.Experimental
MethotrexateThe risk or severity of adverse effects can be increased when Methotrexate is combined with Anthrax immune globulin human.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Anthrax immune globulin human.Approved, Vet Approved
MilatuzumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Milatuzumab.Investigational
Mirvetuximab SoravtansineThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Mirvetuximab Soravtansine.Investigational
MitomycinThe risk or severity of adverse effects can be increased when Mitomycin is combined with Anthrax immune globulin human.Approved
MitoxantroneThe risk or severity of adverse effects can be increased when Mitoxantrone is combined with Anthrax immune globulin human.Approved, Investigational
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Anthrax immune globulin human.Investigational
MogamulizumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Mogamulizumab.Investigational
MometasoneThe risk or severity of adverse effects can be increased when Mometasone is combined with Anthrax immune globulin human.Approved, Vet Approved
MotavizumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Motavizumab.Investigational
MoxestrolMoxestrol may increase the thrombogenic activities of Anthrax immune globulin human.Experimental
MuromonabThe risk or severity of adverse effects can be increased when Muromonab is combined with Anthrax immune globulin human.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Anthrax immune globulin human.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Anthrax immune globulin human.Approved
MYO-029The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with MYO-029.Investigational
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Anthrax immune globulin human.Approved, Investigational
Naptumomab EstafenatoxThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Naptumomab Estafenatox.Investigational
NatalizumabThe risk or severity of adverse effects can be increased when Natalizumab is combined with Anthrax immune globulin human.Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when NCX 1022 is combined with Anthrax immune globulin human.Investigational
NebacumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Nebacumab.Experimental
NecitumumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Necitumumab.Approved, Investigational
NelarabineThe risk or severity of adverse effects can be increased when Nelarabine is combined with Anthrax immune globulin human.Approved, Investigational
NilotinibThe risk or severity of adverse effects can be increased when Nilotinib is combined with Anthrax immune globulin human.Approved, Investigational
NimotuzumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Nimotuzumab.Investigational
NivolumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Nivolumab.Approved
ObiltoxaximabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Obiltoxaximab.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Anthrax immune globulin human.Approved, Investigational
OcrelizumabThe therapeutic efficacy of Ocrelizumab can be decreased when used in combination with Anthrax immune globulin human.Approved, Investigational
OfatumumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Ofatumumab.Approved
OlaratumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Olaratumab.Approved, Investigational
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Anthrax immune globulin human.Investigational
OlokizumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Olokizumab.Investigational
OmalizumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Omalizumab.Approved, Investigational
OnartuzumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Onartuzumab.Investigational
OregovomabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Oregovomab.Investigational
OtelixizumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Otelixizumab.Investigational
OxaliplatinThe risk or severity of adverse effects can be increased when Oxaliplatin is combined with Anthrax immune globulin human.Approved, Investigational
OzanezumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Ozanezumab.Investigational
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Anthrax immune globulin human.Approved, Vet Approved
PalbociclibThe risk or severity of adverse effects can be increased when Palbociclib is combined with Anthrax immune globulin human.Approved, Investigational
PalivizumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Palivizumab.Approved, Investigational
PanitumumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Panitumumab.Approved, Investigational
PanobinostatThe risk or severity of adverse effects can be increased when Panobinostat is combined with Anthrax immune globulin human.Approved, Investigational
PaquinimodThe risk or severity of adverse effects can be increased when Paquinimod is combined with Anthrax immune globulin human.Investigational
ParamethasoneThe risk or severity of adverse effects can be increased when Paramethasone is combined with Anthrax immune globulin human.Approved
PatritumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Patritumab.Investigational
PazopanibThe risk or severity of adverse effects can be increased when Pazopanib is combined with Anthrax immune globulin human.Approved
PegaspargaseThe risk or severity of adverse effects can be increased when Pegaspargase is combined with Anthrax immune globulin human.Approved, Investigational
PembrolizumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Pembrolizumab.Approved
PemetrexedThe risk or severity of adverse effects can be increased when Pemetrexed is combined with Anthrax immune globulin human.Approved, Investigational
PentostatinThe risk or severity of adverse effects can be increased when Pentostatin is combined with Anthrax immune globulin human.Approved, Investigational
PertuzumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Pertuzumab.Approved
PexelizumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Pexelizumab.Investigational
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Anthrax immune globulin human.Approved, Investigational
PirarubicinThe risk or severity of adverse effects can be increased when Pirarubicin is combined with Anthrax immune globulin human.Investigational
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Anthrax immune globulin human.Approved, Investigational
Polatuzumab VedotinThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Polatuzumab Vedotin.Investigational
Polyestradiol phosphatePolyestradiol phosphate may increase the thrombogenic activities of Anthrax immune globulin human.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Anthrax immune globulin human.Approved
PralatrexateThe risk or severity of adverse effects can be increased when Pralatrexate is combined with Anthrax immune globulin human.Approved, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Prasterone is combined with Anthrax immune globulin human.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Anthrax immune globulin human.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Anthrax immune globulin human.Approved, Investigational
PrednisoloneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Anthrax immune globulin human.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Prednisone is combined with Anthrax immune globulin human.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Anthrax immune globulin human.Approved, Experimental, Investigational
PRO 140The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with PRO 140.Investigational
PRO-542The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with PRO-542.Investigational
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Anthrax immune globulin human.Approved, Investigational
PromestrienePromestriene may increase the thrombogenic activities of Anthrax immune globulin human.Investigational
QuinestrolQuinestrol may increase the thrombogenic activities of Anthrax immune globulin human.Approved
R1507The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with R1507.Investigational
RacotumomabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Racotumomab.Investigational
RamucirumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Ramucirumab.Approved, Investigational
RanibizumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Ranibizumab.Approved
RaxibacumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Raxibacumab.Approved
ReslizumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Reslizumab.Approved, Investigational
RI 624The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with RI 624.Investigational
RIGScan CR49The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with RIGScan CR49.Investigational
RilonaceptThe risk or severity of adverse effects can be increased when Rilonacept is combined with Anthrax immune globulin human.Approved, Investigational
RilotumumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Rilotumumab.Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Rimexolone is combined with Anthrax immune globulin human.Approved
RituximabThe risk or severity of adverse effects can be increased when Rituximab is combined with Anthrax immune globulin human.Approved
RobatumumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Robatumumab.Investigational
RomosozumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Romosozumab.Investigational
RontalizumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Rontalizumab.Investigational
RuxolitinibThe risk or severity of adverse effects can be increased when Ruxolitinib is combined with Anthrax immune globulin human.Approved
Sacituzumab govitecanThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Sacituzumab govitecan.Investigational
SarilumabThe risk or severity of infection can be increased when Sarilumab is combined with Anthrax immune globulin human.Approved, Investigational
SecoisolariciresinolSecoisolariciresinol may increase the thrombogenic activities of Anthrax immune globulin human.Investigational
SecukinumabThe risk or severity of adverse effects can be increased when Secukinumab is combined with Anthrax immune globulin human.Approved
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Anthrax immune globulin human.Investigational
SeocalcitolThe risk or severity of adverse effects can be increased when Seocalcitol is combined with Anthrax immune globulin human.Experimental, Investigational
SeribantumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Seribantumab.Investigational
SibrotuzumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Sibrotuzumab.Investigational
SiltuximabThe risk or severity of adverse effects can be increased when Siltuximab is combined with Anthrax immune globulin human.Approved, Investigational
SiplizumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Siplizumab.Investigational
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Anthrax immune globulin human.Approved, Investigational
SirukumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Sirukumab.Investigational
SolanezumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Solanezumab.Investigational
SorafenibThe risk or severity of adverse effects can be increased when Sorafenib is combined with Anthrax immune globulin human.Approved, Investigational
SteproninThe risk or severity of adverse effects can be increased when Stepronin is combined with Anthrax immune globulin human.Approved
StreptozocinThe risk or severity of adverse effects can be increased when Streptozocin is combined with Anthrax immune globulin human.Approved, Investigational
SulesomabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Sulesomab.Approved
SunitinibThe risk or severity of adverse effects can be increased when Sunitinib is combined with Anthrax immune globulin human.Approved, Investigational
SYM001The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with SYM001.Investigational
Synthetic Conjugated Estrogens, ASynthetic Conjugated Estrogens, A may increase the thrombogenic activities of Anthrax immune globulin human.Approved
Synthetic Conjugated Estrogens, BSynthetic Conjugated Estrogens, B may increase the thrombogenic activities of Anthrax immune globulin human.Approved
TabalumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Tabalumab.Investigational
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Anthrax immune globulin human.Approved, Investigational
TanezumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Tanezumab.Investigational
TarextumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Tarextumab.Investigational
TB-402The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with TB-402.Investigational
Technetium Tc-99m arcitumomabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Technetium Tc-99m arcitumomab.Approved, Investigational
TemozolomideThe risk or severity of adverse effects can be increased when Temozolomide is combined with Anthrax immune globulin human.Approved, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Temsirolimus is combined with Anthrax immune globulin human.Approved
TeniposideThe risk or severity of adverse effects can be increased when Teniposide is combined with Anthrax immune globulin human.Approved
TeplizumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Teplizumab.Investigational
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Anthrax immune globulin human.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Anthrax immune globulin human.Approved
Tetanus Immune GlobulinThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Tetanus Immune Globulin.Approved
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Anthrax immune globulin human.Approved, Investigational, Withdrawn
ThiotepaThe risk or severity of adverse effects can be increased when Thiotepa is combined with Anthrax immune globulin human.Approved, Investigational
TiboloneTibolone may increase the thrombogenic activities of Anthrax immune globulin human.Approved, Investigational
TildrakizumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Tildrakizumab.Approved
TioguanineThe risk or severity of adverse effects can be increased when Tioguanine is combined with Anthrax immune globulin human.Approved
TixocortolThe risk or severity of adverse effects can be increased when Tixocortol is combined with Anthrax immune globulin human.Approved, Withdrawn
TNX-901The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with TNX-901.Investigational
TocilizumabThe risk or severity of adverse effects can be increased when Tocilizumab is combined with Anthrax immune globulin human.Approved
TofacitinibThe risk or severity of adverse effects can be increased when Tofacitinib is combined with Anthrax immune globulin human.Approved, Investigational
TopotecanThe risk or severity of adverse effects can be increased when Topotecan is combined with Anthrax immune globulin human.Approved, Investigational
TositumomabThe risk or severity of adverse effects can be increased when Tositumomab is combined with Anthrax immune globulin human.Approved, Investigational
TovetumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Tovetumab.Investigational
TrabectedinThe risk or severity of adverse effects can be increased when Trabectedin is combined with Anthrax immune globulin human.Approved, Investigational
TralokinumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Tralokinumab.Investigational
TrastuzumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Trastuzumab.Approved, Investigational
Trastuzumab emtansineThe risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Anthrax immune globulin human.Approved, Investigational
TRC105The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with TRC105.Investigational
TremelimumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Tremelimumab.Investigational
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Anthrax immune globulin human.Approved, Investigational, Nutraceutical
TriamcinoloneThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Anthrax immune globulin human.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Anthrax immune globulin human.Investigational
TrofosfamideThe risk or severity of adverse effects can be increased when Trofosfamide is combined with Anthrax immune globulin human.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Anthrax immune globulin human.Approved
UstekinumabThe risk or severity of adverse effects can be increased when Ustekinumab is combined with Anthrax immune globulin human.Approved, Investigational
VedolizumabThe risk or severity of adverse effects can be increased when Vedolizumab is combined with Anthrax immune globulin human.Approved
VeltuzumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Veltuzumab.Investigational
VilanterolThe risk or severity of adverse effects can be increased when Vilanterol is combined with Anthrax immune globulin human.Approved
VinblastineThe risk or severity of adverse effects can be increased when Vinblastine is combined with Anthrax immune globulin human.Approved
VincristineThe risk or severity of adverse effects can be increased when Vincristine is combined with Anthrax immune globulin human.Approved, Investigational
VindesineThe risk or severity of adverse effects can be increased when Vindesine is combined with Anthrax immune globulin human.Approved, Investigational
VinorelbineThe risk or severity of adverse effects can be increased when Vinorelbine is combined with Anthrax immune globulin human.Approved, Investigational
VisilizumabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Visilizumab.Investigational
VoclosporinThe risk or severity of adverse effects can be increased when Voclosporin is combined with Anthrax immune globulin human.Investigational
VolociximabThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Volociximab.Investigational
XmAb 2513The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with XmAb 2513.Investigational
XTL-001The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with XTL-001.Investigational
ZeranolZeranol may increase the thrombogenic activities of Anthrax immune globulin human.Vet Approved
Food Interactions
Not Available

References

General References
  1. Mytle N, Hopkins RJ, Malkevich NV, Basu S, Meister GT, Sanford DC, Comer JE, Van Zandt KE, Al-Ibrahim M, Kramer WG, Howard C, Daczkowski N, Chakrabarti AC, Ionin B, Nabors GS, Skiadopoulos MH: Evaluation of intravenous anthrax immune globulin for treatment of inhalation anthrax. Antimicrob Agents Chemother. 2013 Nov;57(11):5684-92. doi: 10.1128/AAC.00458-13. Epub 2013 Aug 26. [PubMed:23979731]
External Links
PubChem Substance
347910401
Drugs.com
Drugs.com Drug Page
Wikipedia
Anthrax_immune_globulin
AHFS Codes
  • 80:12.00 — Vaccines
FDA label
Download (4.37 MB)

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
LiquidIntravenous60 [iU]/35mL
SolutionIntravenous60 unit
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Bacillus anthracis
Pharmacological action
Yes
Actions
Antibody
General Function
Metal ion binding
Specific Function
One of the three proteins composing the anthrax toxin, the agent which infects many mammalian species and that may cause death. PA binds to a receptor (ATR) in sensitive eukaryotic cells, thereby f...
Gene Name
pagA
Uniprot ID
P13423
Uniprot Name
Protective antigen
Molecular Weight
85810.325 Da

Drug created on May 11, 2015 12:08 / Updated on April 17, 2018 01:10